A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)

Study Summary

This is a Phase 1/2, multicenter, open-label, dose-exploration (Phase 1) and dose-expansion (Phase 2) study to evaluate the safety, tolerability, PK/PD, and efficacy of BEAM-302 in adult patients with AATD-associated lung disease and/or liver disease and to determine the optimal biological dose (OBD).

Conditions

Alpha 1-Antitrypsin Deficiency

Interventions / Drugs

BEAM-302

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment106 participants

Primary Completion—

Lead SponsorBeam Therapeutics Inc.

Data Retrieved2026-04-11 04:07:17.424712+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.